surmount-1 tirzepatide non-diabetic obesity weight loss SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide after intensive lifestyle intervention

52% of the semaglutide-treated test subjects achieved a weight loss response of greater than 5%, while a weight loss response of greater than 10% was achieved by 21% of the test subjects treated with the peptide

Programs with medical supervision lead to better results when they handle potential side effects

The bigger issue is uncertainty

1-3 If you have T2DM, always follow your GPs advice to monitor your blood sugar levels closely while taking Ozempic and discuss whether adjustments to your other diabetes medications are needed to reduce the risk of hypoglycaemia

People plateau on semaglutide and want the greater weight loss potential of tirzepatide

Your provider sets your dosing based on your lab results, symptoms, and goals